1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

  • January 2017
  • ID: 4699206
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Summary

Immunology is one of the largest therapy areas, with a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 539 immunology pipeline products that act on a first-in-class molecular target, representing 40% of the total immunology pipeline for which the molecular target was disclosed.

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

The immune system is highly complex and has a high degree of functional redundancy. For example, the functions of cytokines and chemokines, which serve as endogenous systemic chemical messengers for the immune system, are overlapping and often incompletely characterized. While this presents numerous molecular targets for potential pharmaceutical intervention across multiple diseases, it also creates difficulty in selecting the appropriate target or combination of targets for these drugs.
There are a total of 253 distinct first-in-class molecular targets in development, of which 65 were found to be in development across multiple indications. Cytokines and intracellular signal transducers were strongly represented amongst the most promising versatile first-in-class molecular targets.

Between 2006 and 2016, a total of 497 licensing deals and 433 co-development deals in the immunology therapy area were identified as having been completed, with a combined aggregate value of US$46 billion. This high level of deal-making activity is indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations in order to mitigate some of the risks associated with drug development in the immunology therapy area.

The report “Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential” helps you to understand the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products, also helps to identify current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market. Additionally, it will insights to review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment and identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing.

Scope

- What are the key points of overlap in the pathophysiology of immune disorders?
- What is the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products?
- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- Do immunology products attract high deal values, and which specific product types are able to attract the highest values?
- Which molecule types and molecular targets dominate the deals landscape?

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market.
Review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the immunology pipeline have been assessed and ranked according to clinical potential, and the most promising early-stage targets have been further reviewed in greater detail.
- Identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($6995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019

Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019Summary Medical Devices sector report, “Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019" provides an overview ...

Global Immunology Partnering 2014-2019: Deal trends, players and financials

Global Immunology Partnering 2014-2019: Deal trends, players and financials

  • $ 2995
  • December 2019

Global Immunology Partnering 2014 to 2019 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.Trends in Immunology ...

Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019

Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019’; Nuclear Receptor ROR Gamma (Nuclear Recepto ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on